Evidence map›Paper›PMID 30022069›Full record

ArticleScientific reports2018

Crystal structure of an L chain optimised 14F7 anti-ganglioside Fv suggests a unique tumour-specificity through an unusual H-chain CDR3 architecture.

Kaare Bjerregaard-Andersen, Hedda Johannesen, Noha Abdel-Rahman, Julie Elisabeth Heggelund, Helene Mykland Hoås, Fana Abraha, Paula A Bousquet, Lene Støkken Høydahl, Daniel Burschowsky, Gertrudis Rojas and 3 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. The Structural Complexity and Animal Tissue Distribution ofFrontiers in molecular biosciences · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 7 institutions in 5 countries.

Kaare Bjerregaard-AndersenDepartment of Chemistry, University of Oslo, NO-0315 Oslo, Norway. kaarebj@kjemi.uio.no.ORCID 0000-0003-3609-3408
Hedda JohannesenDepartment of Chemistry, University of Oslo, NO-0315 Oslo, Norway.
Noha Abdel-RahmanDepartment of Chemistry, University of Oslo, NO-0315 Oslo, Norway.
Julie Elisabeth HeggelundDepartment of Chemistry, University of Oslo, NO-0315 Oslo, Norway.ORCID 0000-0001-7805-1754
Helene Mykland HoåsDepartment of Chemistry, University of Oslo, NO-0315 Oslo, Norway.
Fana AbrahaSchool of Chemistry, University College Dublin, Belfield, Dublin, 4, Ireland.
Paula A BousquetDepartment of Chemistry, University of Oslo, NO-0315 Oslo, Norway.
Lene Støkken HøydahlCentre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, NO-0372 Oslo, Norway.
Daniel BurschowskyDepartment of Chemistry, University of Oslo, NO-0315 Oslo, Norway.
Gertrudis RojasCenter of Molecular Immunology, Calle 216 esq 15, Atabey, Playa, La Habana, CP, 11300, Cuba.
Stefan OscarsonSchool of Chemistry, University College Dublin, Belfield, Dublin, 4, Ireland.
Geir Åge LøsetCentre for Immune Regulation and Department of Immunology, University of Oslo and Oslo University Hospital, NO-0372 Oslo, Norway. g.a.loset@ibv.uio.no.ORCID 0000-0002-5257-8571
Ute KrengelDepartment of Chemistry, University of Oslo, NO-0315 Oslo, Norway. ute.krengel@kjemi.uio.no.ORCID 0000-0001-6688-8151
University of Oslo · NOOslo University Hospital · NOUniversity College Dublin · IECenter of Molecular Immunology (Cuba) · CUMansoura University · EGUniversity of Leeds · GBUniversity of Leicester · GB

Funding

Norges Forskningsråd (Research Council of Norway) 247730Science Foundation Ireland (SFI) 08/SRC/B1393Science Foundation Ireland (SFI) 13/IA/1959
6 · The paper itself

Abstract

Targeted cancer immunotherapy offers increased efficacy concomitantly with reduced side effects. One antibody with promising clinical potential is 14F7, which specifically recognises the NeuGc GM3 ganglioside. This antigen is found in the plasma membrane of a range of tumours, but is essentially absent from healthy human cells. 14F7 can discriminate NeuGc GM3 from the very similar NeuAc GM3, a common component of cell membranes. The molecular basis for this unique specificity is poorly understood. Here we designed and expressed 14F7-derived single-chain Fvs (scFvs), which retained the specificity of the parent antibody. Detailed expression and purification protocols are described as well as the synthesis of the NeuGc GM3 trisaccharide. The most successful scFv construct, which comprises an alternative variable light chain (V

Indexed as

Antibodies, MonoclonalCrystallography, X-RayG(M3) GangliosideHumansImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsImmunoglobulin Variable RegionNeoplasmsProtein ConformationSingle-Chain AntibodiesAntibodies, MonoclonalG(M3) GangliosideImmunoglobulin Heavy ChainsImmunoglobulin Light ChainsImmunoglobulin Variable RegionSingle-Chain Antibodies

Identifiers

PMID30022069
PMCPMC6052152
OpenAlexW2846306577

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.